PH12021552819A1 - A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator - Google Patents
A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulatorInfo
- Publication number
- PH12021552819A1 PH12021552819A1 PH1/2021/552819A PH12021552819A PH12021552819A1 PH 12021552819 A1 PH12021552819 A1 PH 12021552819A1 PH 12021552819 A PH12021552819 A PH 12021552819A PH 12021552819 A1 PH12021552819 A1 PH 12021552819A1
- Authority
- PH
- Philippines
- Prior art keywords
- positive allosteric
- allosteric modulator
- tetrahydroisoquinoline derivative
- substituted tetrahydroisoquinoline
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19183641 | 2019-07-01 | ||
| PCT/EP2020/068181 WO2021001286A1 (en) | 2019-07-01 | 2020-06-29 | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12021552819A1 true PH12021552819A1 (en) | 2022-09-28 |
Family
ID=67137842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2021/552819A PH12021552819A1 (en) | 2019-07-01 | 2020-06-29 | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US12358890B2 (https=) |
| EP (1) | EP3993795B1 (https=) |
| JP (1) | JP7618597B2 (https=) |
| KR (1) | KR102949226B1 (https=) |
| CN (1) | CN114008032B (https=) |
| AR (1) | AR119317A1 (https=) |
| AU (1) | AU2020299705B2 (https=) |
| BR (1) | BR112021022379A2 (https=) |
| CA (1) | CA3139622A1 (https=) |
| CL (1) | CL2021002949A1 (https=) |
| CO (1) | CO2021017740A2 (https=) |
| EC (1) | ECSP22007557A (https=) |
| IL (1) | IL289317B2 (https=) |
| MA (1) | MA56445A (https=) |
| MX (1) | MX2021015872A (https=) |
| MY (1) | MY210362A (https=) |
| PE (1) | PE20220373A1 (https=) |
| PH (1) | PH12021552819A1 (https=) |
| SA (1) | SA521431274B1 (https=) |
| SG (1) | SG11202112539XA (https=) |
| TW (1) | TWI842923B (https=) |
| UA (1) | UA130613C2 (https=) |
| WO (1) | WO2021001286A1 (https=) |
| ZA (1) | ZA202109194B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2976784T3 (es) | 2020-10-07 | 2024-08-08 | Lilly Co Eli | Derivados de fenil-3,4-dihidroisoquinolin-2(1H)-il-etan-1-ona como moduladores alostéricos positivos del receptor de dopamina D1 |
| EP4304577A1 (en) * | 2021-03-09 | 2024-01-17 | Eli Lilly And Co. | Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2679735A1 (en) | 2007-03-01 | 2008-09-12 | Janssen Pharmaceutica N.V. | Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor |
| KR101284796B1 (ko) | 2011-10-05 | 2013-07-10 | (주)포인트엔지니어링 | 캔 패지키 타입의 광 디바이스 제조 방법 및 이에 의해 제조된 광 디바이스 |
| IN2014CN03234A (https=) | 2011-11-03 | 2015-07-03 | Merck Sharp & Dohme | |
| JO3316B1 (ar) | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
| WO2016055479A1 (en) | 2014-10-08 | 2016-04-14 | Ucb Biopharma Sprl | Tetrahydroisoquinoline derivatives |
| CN108884050B (zh) * | 2016-04-13 | 2022-07-05 | Ucb生物制药私人有限公司 | 四氢异喹啉衍生物 |
| JP7090099B2 (ja) * | 2017-03-16 | 2022-06-23 | エフ．ホフマン－ラ ロシュ アーゲー | Ａｔｘインヒビターとしての新規二環式化合物 |
| TWI725408B (zh) | 2018-04-20 | 2021-04-21 | 美商美國禮來大藥廠 | 多巴胺d1受體正向異位調節劑 |
-
2020
- 2020-06-29 IL IL289317A patent/IL289317B2/en unknown
- 2020-06-29 CN CN202080043673.9A patent/CN114008032B/zh active Active
- 2020-06-29 CA CA3139622A patent/CA3139622A1/en active Pending
- 2020-06-29 BR BR112021022379A patent/BR112021022379A2/pt unknown
- 2020-06-29 SG SG11202112539XA patent/SG11202112539XA/en unknown
- 2020-06-29 MX MX2021015872A patent/MX2021015872A/es unknown
- 2020-06-29 PE PE2021002217A patent/PE20220373A1/es unknown
- 2020-06-29 EP EP20735361.6A patent/EP3993795B1/en active Active
- 2020-06-29 WO PCT/EP2020/068181 patent/WO2021001286A1/en not_active Ceased
- 2020-06-29 US US17/621,871 patent/US12358890B2/en active Active
- 2020-06-29 JP JP2021575050A patent/JP7618597B2/ja active Active
- 2020-06-29 KR KR1020227002603A patent/KR102949226B1/ko active Active
- 2020-06-29 MA MA056445A patent/MA56445A/fr unknown
- 2020-06-29 UA UAA202106080A patent/UA130613C2/uk unknown
- 2020-06-29 AU AU2020299705A patent/AU2020299705B2/en active Active
- 2020-06-29 MY MYPI2021006863A patent/MY210362A/en unknown
- 2020-06-29 PH PH1/2021/552819A patent/PH12021552819A1/en unknown
- 2020-06-30 TW TW109122034A patent/TWI842923B/zh active
- 2020-06-30 AR ARP200101852A patent/AR119317A1/es unknown
-
2021
- 2021-11-08 CL CL2021002949A patent/CL2021002949A1/es unknown
- 2021-11-17 ZA ZA2021/09194A patent/ZA202109194B/en unknown
- 2021-12-23 CO CONC2021/0017740A patent/CO2021017740A2/es unknown
- 2021-12-30 SA SA521431274A patent/SA521431274B1/ar unknown
-
2022
- 2022-01-31 EC ECSENADI20227557A patent/ECSP22007557A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3139622A1 (en) | 2021-01-07 |
| JP2022537994A (ja) | 2022-08-31 |
| IL289317B1 (en) | 2025-05-01 |
| EP3993795B1 (en) | 2026-04-22 |
| IL289317B2 (en) | 2025-09-01 |
| SG11202112539XA (en) | 2021-12-30 |
| IL289317A (en) | 2022-02-01 |
| ZA202109194B (en) | 2023-11-29 |
| TWI842923B (zh) | 2024-05-21 |
| MA56445A (fr) | 2022-05-11 |
| AU2020299705B2 (en) | 2026-03-19 |
| WO2021001286A1 (en) | 2021-01-07 |
| CN114008032B (zh) | 2023-11-10 |
| ECSP22007557A (es) | 2022-02-25 |
| AR119317A1 (es) | 2021-12-09 |
| SA521431274B1 (ar) | 2024-01-09 |
| CL2021002949A1 (es) | 2022-07-15 |
| JP7618597B2 (ja) | 2025-01-21 |
| KR102949226B1 (ko) | 2026-04-06 |
| US20220251064A1 (en) | 2022-08-11 |
| US12358890B2 (en) | 2025-07-15 |
| CO2021017740A2 (es) | 2022-01-17 |
| BR112021022379A2 (pt) | 2022-03-08 |
| PE20220373A1 (es) | 2022-03-16 |
| UA130613C2 (uk) | 2026-04-01 |
| TW202115009A (zh) | 2021-04-16 |
| CN114008032A (zh) | 2022-02-01 |
| AU2020299705A1 (en) | 2021-12-09 |
| KR20220029687A (ko) | 2022-03-08 |
| EP3993795A1 (en) | 2022-05-11 |
| MX2021015872A (es) | 2022-02-03 |
| MY210362A (en) | 2025-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ777871A (en) | Small molecule modulators of il-17 | |
| SA521431279B1 (ar) | D1 مشتق تتراهيدرو إيزوكينولين بديل كمعدِّل تفارغي إيجابي | |
| PH12016500777A1 (en) | Compositions and methods for modulating farnesoid x receptors | |
| EA201590118A1 (ru) | Производные пирролидина и их применение в качестве модуляторов пути активации комплемента | |
| PH12018500777A1 (en) | Farnesoid x receptor modulators | |
| EA201590200A1 (ru) | Модуляторы пути активации комплемента и их применение | |
| GEP20207102B (en) | Sulfonamides as modulators of sodium channels | |
| UA109220C2 (uk) | Похідні (4-фенілімідазол-2-іл)етиламіну як модулятори натрієвих каналів | |
| MY195194A (en) | Substituted Indoline Derivatives as Dengue Viral Replication Inhibitors | |
| ECSP088854A (es) | Moduladores bencimidazolicos de vr1 | |
| MY181959A (en) | Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes | |
| EA201891377A1 (ru) | ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| MX362919B (es) | Moduladores del receptor acoplado a proteína-g 120 (gpr120) de ácido biciclo-[2.2.1]. | |
| SA521431274B1 (ar) | مشتق تتراهيدرو إيزوكينولين بديل كمعدِّل تفارغي إيجابي d1 | |
| EA201792594A1 (ru) | Положительные аллостерические модуляторы мусаринового рецептора м1 | |
| EA201991728A1 (ru) | Модуляторы аденозиновых рецепторов a | |
| ZA202305336B (en) | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator | |
| MX2023001906A (es) | Diarilureas como moduladores alostericos de cannabinoide cb1. | |
| MX385475B (es) | Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa | |
| EA202191053A1 (ru) | Соединения 2-формил-3-гидроксифенилоксиметила в качестве модулятора гемоглобина | |
| BR112019024708A2 (pt) | composições farmacêuticas de liberação prolongada retardada | |
| TN2013000241A1 (en) | Compositions and methods for modulating fxr |